Analytical Chemistry and Pharmacology Core Facility

分析化学和药理学核心设施

• 批准号: 8392179
• 负责人: WILLIAM C ZAMBONI
• 金额: $ 22.9万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8392179
• 关键词: Affect; Analytical Chemistry; Antineoplastic Agents; Biological; Biological Assay; Cancer Center; Cancer Hospital; Clinical; Clinical Research; Clinical Trials Unit; Collaborations; Contracts; Core Facility; Cutaneous Melanoma; Data; Data Analyses; Data Quality; Development; Documentation; Drug Formulations; Drug Kinetics; Ensure; Funding; Future; Genetically Engineered Mouse; Goals; Grant; Housing; Ice; Industry; Investigation; Investments; Licensing; Methodology; Methods; Molecular; North Carolina; Patients; Pharmaceutical Preparations; Pharmacodynamics; Pharmacologic Substance; Pharmacology; Phase; Pre-Clinical Model; Process; Program Development; Recruitment Activity; Research; Research Infrastructure; Research Personnel; Resources; Role; Sampling; Services; Staging; Strategic Planning; Technology; Therapeutic; Toxicology; Validation; Xenograft procedure; cost; cost effective; drug development; good laboratory practice; melanoma; member; mouse model; nanoparticle; novel; oncology; operation; pre-clinical; preclinical study; programs; small molecule; tumor

Analytical Chemistry and Pharmacology Core Facility The goal of this core is to support the translational development of small molecule and nanoparticle anticancer agents via analytical chemistry and pharmacologic infrastructure and methodologies. The expansion of the MolecularTherapeutics Program, development of preclinical models used to evaluate anticancer agents and the opening of new North Carolina Cancer Hospital's Clinical Trials Unit created the demand for applied pharmacology services. The recruitment of Dr. Zamboni and the substantial investment of cancer center institutional funds launched the core and its operations. This new core is comprised of the Translational Oncology and Nanoparticle Drug Development Initiative (TOND2I) Lab (opened in March'09) and the UNC GLP Bioanalytical Facility (will open in Feb'10). The technologies and resources offered by this core were not previously available at UNC. Moreover, the UNC GLP Bioanalytical Facility is one of the few such GLP labs that exist in an academic center. The core resources will expand researchers' horizons and funding by providing outstanding expertise in performing analytical and pharmacology studies, providing the highest quality of data and performing these studies in a cost effective manner. The core's sen/ices consist of: analytical studies at GLP and non-GLP levels; development of drug formulations; development and validation of analytical assays In biological matrices; sample analysis; pharmacokinetic and pharmacodynamic data analysis; and specialized methods for nanoparticle pharmacology. An example of this is the collaboration with Drs. Sharpless, Collichio and Ollila, where we are currently evaluating the factors affecting the tumor delivery of anticancer agents in xenograft and genetically engineered mouse models (GEMM) of melanoma and in patients with cutaneous melanoma. Future plans are to expand the research of UNC LCCC members and use the resources of this core to recruit novel anticancer agents to UNC. The core requests $160,846, representing 15% of its operating costs; Cancer Center members constitute 96% of the core's users. This new core will be a tremendous asset to the center.

分析化学和药理学核心设施 该核心的目标是通过分析化学和药理学基础设施和方法支持小分子和纳米颗粒抗癌药物的转化开发。分子治疗计划的扩展、用于评估抗癌药物的临床前模型的开发以及新的北卡罗来纳州癌症医院临床试验部门的开设创造了 应用药理学服务的需求。 Zamboni 博士的招募和癌症中心机构资金的大量投资启动了核心及其运营。这个新的核心由转化肿瘤学和纳米颗粒药物开发计划 (TOND2I) 实验室（将于 2009 年 3 月开放）和北卡罗来纳大学 GLP 生物分析设施（将于 2010 年 2 月开放）组成。该核心提供的技术和资源以前在北卡罗来纳大学是无法获得的。此外，北卡罗来纳大学 GLP 生物分析设施是学术中心内为数不多的此类 GLP 实验室之一。核心资源将通过提供进行分析和药理学研究的杰出专业知识来扩大研究人员的视野和资金，提供 最高质量的数据并以具有成本效益的方式进行这些研究。 核心服务包括： GLP 和非 GLP 水平的分析研究；药物配方的开发；生物基质分析测定的开发和验证；样品分析；药代动力学和药效学数据分析；以及纳米颗粒药理学的专门方法。与 Drs 的合作就是一个例子。 Sharpless、Colchio 和 Ollila，我们目前正在评估影响黑色素瘤异种移植和基因工程小鼠模型 (GEMM) 以及皮肤黑色素瘤患者中抗癌药物的肿瘤递送的因素。 未来的计划是扩大 UNC LCCC 成员的研究，并利用该核心的资源为 UNC 招募新型抗癌药物。核心请求160,846美元，占其运营成本的15%；癌症中心会员占核心用户的96%。这个新的核心将成为该中心的巨大资产。